Ocular Therapeutix begins enrollment for phase 3 SOL-R clinical trial for wet AMD

News
Article

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

Doctor conducting Amsler grid test with patient Image credit: AdobeStock/AndreyPopov

Image credit: AdobeStock/AndreyPopov

Ocular Therapeutix announced the first patients have been enrolled in its Phase 3 SOL-R trial (NCT06495918) evaluating its axitinib intravitreal implant, also known as OTX-TKI (AXPAXLI) for the treatment of patients with wet age-related macular degeneration (wet AMD).

AXPAXLI, an axitinib intravitreal implant, is a bioresorbable, hydrogel implant incorporating axitinib. Axitinib is a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties.

Pravin U. Dugel, MD, executive chairman, president and CEO of Ocular Therapeutix commented on AXPAXLI and the company’s other phase 3 trial, SOL-1, in a press release.1

“Our first Phase 3 trial, SOL-1, is intended to show that AXPAXLI can safely and durably maintain visual acuity in patients with wet AMD. SOL-R is intended to build on that by providing physicians with important evidence regarding the potential to re-dose AXPAXLI every 6 months, which better aligns with a likely ‘real world’ experience,” said Dugel.

Dugel commented on the trial design by saying, “SOL-R will initially enroll patients who do not qualify to be randomized in SOL-1. Subsequently, SOL-R will be opened to direct enrollment of patients who are treatment naïve or diagnosed with wet AMD within 3 months prior to enrollment. Patients enrolled in SOL-R are similar to those enrolled in our successful U.S. Phase 1 study, with further enrichment through multiple aflibercept loading doses. Further, these patients are evaluated to limit retinal fluid fluctuations between visits prior to randomization, increasing our confidence in the study’s potential success.”

The phase 3 SOL-R clinical trial will evaluate AXPAXLI in a multi-center, double-masked, randomized (2:2:1), 3-arm study. Goals of the study are to randomize approximately 825 patients globally who are treatment naïve or have been diagnosed with wet AMD within 3 months prior to enrollment.

The 1-year, non-inferiority study includes multiple loading doses of aflibercept and monitoring to exclude those with significant retinal fluid fluctuations. Patients in the first arm will be randomized to receive a single dose of AXPAXLI at Day 1 and will be re-dosed at Week 24. Patients in the second arm will receive aflibercept (2 mg) on-label every 8 weeks. While patients in the third arm will receive a single dose of aflibercept (8 mg) at Day 1 and will be re-dosed at Week 24, aligned to the AXPAXLI treatment arm for adequate masking.1,2

The primary endpoint for the SOL-R clinical trial is non-inferiority in mean best corrected visual acuity (BCVA) change from baseline between the AXPAXLI and on-label aflibercept (2 mg) arms at one year.1,2

References:
  1. Ocular Therapeutix announces first patients enrolled in Phase 3 SOL-R wet AMD study. News Release. July 30, 2024. Accessed July 30, 2024. https://www.globenewswire.com/news-release/2024/07/30/2920887/0/en/Ocular-Therapeutix-Announces-First-Patients-Enrolled-in-Phase-3-SOL-R-Wet-AMD-Study.html
  2. Study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration. NCT06495918. Accessed July 30, 2024. https://clinicaltrials.gov/study/NCT06495918?id=NCT06495918&aggFilters=status:not%20rec&rank=1&tab=table
Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.